Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Titre officiel

A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicentre Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)

Sommaire:

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma

Description de l'essai

Primary Outcome:

  • Progression Free Survival (PFS) for Arm A vs Arm C
Secondary Outcome:
  • Progression Free Survival (PFS) for Arm B vs Arm C
  • Overall Survival (OS) for Arm A vs Arm C
  • Overall Survival (OS) for Arm B vs Arm C
This is a Phase III, parallel, randomized, open-label, sponsor-blinded, 3-arm, multicentre, international study assessing the efficacy and safety of durvalumab + tremelimumab + TACE with or without lenvatinib compared with TACE alone in participants with locoregional HCC not amenable to curative therapy (eg, surgical resection, transplantation, or ablation).

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer